This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Exact Sciences Stock (NASDAQ:EXAS) Get Exact Sciences alerts:Sign Up Key Stats Today's Range$104.91▼$104.9150-Day Range$102.25▼$104.9152-Week Range$38.81▼$104.98VolumeN/AAverage Volume3.55 million shsMarket Capitalization$20.03 billionP/E RatioN/ADividend YieldN/APrice Target$92.13Consensus RatingReduce Company Overview Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults. Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development. In 2019, the company completed the acquisition of Genomic Health, bringing Oncotype DX® diagnostic tests into its offerings. These tests assess gene expression profiles in breast, prostate and other cancers to help guide treatment decisions, furthering Exact’s mission to advance precision oncology. Exact Sciences sells its products primarily in the United States and has extended its reach into selected international markets, including Europe and Australia. The company operates a network of laboratories and works closely with healthcare providers, payers and policy makers to support the adoption of its screening and diagnostic technologies. Exact Sciences also invests in clinical trials and real-world evidence studies to validate and refine its assays. Kevin Conroy, who joined Exact Sciences in 2015 and became president and chief executive officer in 2017, leads the company’s efforts to integrate molecular diagnostics into standard cancer care. Under his leadership, Exact has grown its commercial infrastructure and doubled down on research initiatives aimed at developing next-generation tests for multiple tumor types. The company remains focused on improving patient outcomes through earlier detection and more personalized treatment pathways.AI Generated. May Contain Errors. Read More Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXAS Stock News HeadlinesAbbott Labs shares fall as earnings beat offset by Exact Sciences acquisition dragApril 16, 2026 | proactiveinvestors.comExact Sciences CorporationMarch 26, 2026 | edition.cnn.comI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.May 20 at 1:00 AM | Porter & Company (Ad)Abbott completes acquisition of Exact SciencesMarch 23, 2026 | finance.yahoo.comHow Walgreens’ Pharmacy-Led Cologuard Expansion At Exact Sciences (EXAS) Has Changed Its Investment StoryMarch 22, 2026 | finance.yahoo.com1 Mid-Cap Stock to Consider Right Now and 2 Facing HeadwindsMarch 17, 2026 | finance.yahoo.comExact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026March 17, 2026 | finance.yahoo.comExact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026March 17, 2026 | businesswire.comSee More Headlines EXAS Stock Analysis - Frequently Asked Questions How were Exact Sciences' earnings last quarter? Exact Sciences Corporation (NASDAQ:EXAS) issued its earnings results on Monday, November, 3rd. The medical research company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.11. Exact Sciences's quarterly revenue was up 20.0% compared to the same quarter last year. Read the conference call transcript. Does Exact Sciences have any subsidiaries? Exact Sciences subsidiaries include Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings11/03/2025Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EXAS's financial health is in the Green zone, according to TradeSmith. EXAS has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees7,200Year Founded1995Price Target and Rating Average Price Target for Exact Sciences$92.13 High Price Target$105.00 Low Price Target$46.00 Potential Upside/Downside-12.2%Consensus RatingReduce Rating Score (0-4)1.95 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth2.02Net Income-$207.95 million Net Margins-6.40% Pretax Margin-6.28% Return on Equity0.53% Return on Assets0.22% Debt Debt-to-Equity Ratio0.97 Current Ratio2.43 Quick Ratio2.17 Sales & Book Value Annual Sales$3.25 billion Price / Sales6.17 Cash Flow$1.27 per share Price / Cash Flow82.83 Book Value$12.58 per share Price / Book8.34Miscellaneous Outstanding Shares190,888,000Free Float188,597,000Market Cap$20.03 billion OptionableOptionable Beta1.41 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:EXAS) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
